Encouraging Response Rates and High Mobilization Success with Brentuximab Vedotin Plus GDP in Adult Relapsed/Refractory Classical Hodgkin Lymphoma: A Real-World Study

• BV+GDP achieved an 87.5% complete response rate in adult R/R Hodgkin lymphoma. • All responders demonstrated 100% successful stem-cell mobilization. • The regimen showed a manageable safety profile without unexpected toxicities. • BV+GDP may represent a potential outpatient alternative to inpatient platinum-based salvage regimens. • Outpatient feasibility suggests BV+GDP may offer a potential outpatient alternative to inpatient platinum-based regimens. • To our knowledge, this study represents the first reported adult real-world cohort evaluating BV+GDP. Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging, and achieving metabolic complete response prior to autologous stem cell transplantation (ASCT) is important. GDP is a generally well-tolerated outpatient regimen, while brentuximab vedotin (BV) has demonstrated encouraging activity in salvage combinations. Adult real-world data on BV+GDP remain limited. Eight adult R/R cHL patients received BV+GDP between May 2023 and March 2025. Responses (Lugano 2014), toxicities (CTCAE v5.0), and mobilization outcomes were retrospectively evaluated. Complete response was achieved in 7/8 patients (87.5%). All responders underwent successful stem-cell mobilization and ASCT. Toxicities were manageable, with no febrile neutropenia or renal toxicity observed. At a median follow-up of 10.6 months, all patients remained alive and progression-free. BV+GDP showed encouraging activity with acceptable tolerability, supporting further prospective evaluation.